Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Triomics, founded with a mission to revolutionize oncology research and care through intelligent automation, focuses on leveraging AI to assist cancer care providers. The company offers a generative AI-powered platform designed to manage the growing volume of oncology data, reduce cognitive overload for healthcare staff, and streamline operations. Triomics' solutions include enhancing patient-trial matching, curating data for research and precision medicine, and accelerating trial enrollment and quality improvement projects.
Notable affiliated individuals and investors in Triomics include experts in oncology and AI technology, though specific names are not provided. The company has achieved significant milestones in improving the efficiency of oncology care operations and has made a substantial impact by enabling faster trial enrollments and better data management. Triomics' AI-driven approach has positioned it as a key player in transforming cancer care and research, addressing critical challenges faced by healthcare providers.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Oncology Software
Technology
AI
Tags
Ai Operations
Model Types
SaaS
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Americas
When was Triomics founded?
Triomics was founded in 2020.
Where is Triomics's headquarters located?
Triomics's headquarters is located in San Francisco, CA, US.
When was Triomics's last funding round?
Triomics's most recent funding round was for $11.3M (USD) in February 2023.
How many employees does Triomics have?
Triomics has 50 employees as of Mar 31, 2024.
How much has Triomics raised to-date?
As of July 05, 2023, Triomics has raised a total of $14.1M (USD) since Feb 22, 2023.
Add Comparison
Total Raised to Date
$14.1M
USD
Last Update Feb 22, 2023
Last Deal Details
$11.3M
USD
Feb 22, 2023
Series A
Current Employees
50
(over the past year)
Last updated: Mar 31, 2024
Employee Growth Trend
High
Medium
Low
Hover over data points to see confidence level and exact employee count
No location information available for this company.
Locations
TechCrunch
Triomics raises $15M Series A to automate cancer clinical trials matching
For cancer patients, medicines administered in clinical trials can help save or extend lives. But despite thousands of trials in the United...
May 9, 2024
Is this the right Triomics?
Help us improve our AI - Is this article for the right company?
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts